![MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2âPositive and/or Hormone ReceptorâNegative Breast Cancers in the I-SPY 2 Trial]()
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2âPositive and/or Hormone ReceptorâNegative Breast Cancers in the I-SPY 2 TrialChien, A. Jo; Tripathy, Debasish; Albain, Kathy S.; Symmans, W. Fraser; Rugo, Hope S.; Melisko, Michelle E.; Wallace, Anne M.; Schwab, Richard; Helsten, Teresa; Forero-Torres, Andres; Stringer-Reasor, Erica; Ellis, Erin D.; Kaplan, Henry G.; Nanda, Rita; Jaskowiak, Nora; Murthy, Rashmi; Godellas, Constantine; Boughey, Judy C.; Elias, Anthony D.; Haley, Barbara B.; Kemmer, Kathleen; Isaacs, Claudine; Clark, Amy S.; Lang, Julie E.; Lu, Janice; Korde, Larissa; Edmiston, Kirsten K.; Northfelt, Donald W.; Viscusi, Rebecca K.; Yee, Douglas; Perlmutter, Jane; Hylton, Nola M.; vanât Veer, Laura J.; DeMichele, Angela; Wilson, Amy; Peterson, Garry; Buxton, Meredith B.; Paoloni, Melissa; Clennell, Julia; Berry, Scott; Matthews, Jeffrey B.; Steeg, Katherine; Singhrao, Ruby; Hirst, Gillian L.; Sanil, Ashish; Yau, Christina; Asare, Smita M.; Berry, Donald A.; Esserman, Laura J. · Journal of Clinical Oncology · 2019